|1.||Chen, Zhu: 7 articles (02/2010 - 11/2002)|
|2.||Ley, Timothy J: 6 articles (02/2007 - 09/2003)|
|3.||Kogan, Scott C: 5 articles (12/2007 - 02/2003)|
|4.||Chen, Z: 5 articles (01/2007 - 01/2001)|
|5.||Gallagher, R E: 5 articles (04/2006 - 01/2000)|
|6.||Jing, Yongkui: 5 articles (09/2005 - 08/2002)|
|7.||Müller-Tidow, Carsten: 4 articles (06/2010 - 12/2004)|
|8.||de Thé, H: 4 articles (02/2009 - 06/2001)|
|9.||Zhu, J: 4 articles (09/2008 - 06/2001)|
|10.||Tenen, Daniel G: 4 articles (02/2008 - 02/2003)|
|1.||Acute Promyelocytic Leukemia
12/01/2003 - "[Improved RT-PCR for detection of PML/RARalpha fusion gene in rapid diagnosis of acute promyelocytic leukemia]."
07/01/1996 - "Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia."
01/01/2001 - "Acute promyelocytic leukemia (APL) patients with t(15;17)(PML/RARalpha positive) achieve remission upon t-RA treatment, whereas patients with t(11;17)(PLZF/RARalpha positive) do not. "
07/01/2003 - "This study investigated the clinical characteristics and prognostic relevance of CD34 expression in 47 patients with acute promyelocytic leukemia (APL), showing t(15;17) or PML/RARalpha. "
01/01/2001 - "To study the relationship between the expression level of the PML-RARalpha fusion transcripts and the clinical status and efficiency of the therapy in acute promyelocytic leukemia (APL) patients, we applied a very sensitive and specific real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) system to quantify the dose of PML-RARalpha fusion transcripts in a series of APL patients at distinct disease stages. "
01/01/2004 - "Recent studies also showed that efficient induction of relevant human leukemia in mice by certain oncogenes, such as PML/RARalpha and TEL/ABL, only occurred when they were expressed at a low level or close to pathophysiologically relevant level. "
09/01/2010 - "In summary, our results indicate that ATO in conjunction with ATRA is of potential chemotherapeutic use in PML-RARalpha negative leukemias."
08/01/2009 - "PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors."
12/01/2008 - "In contrast, the leukemia-associated fusion PML-RARalpha induced the degradation of HIPK2. "
02/01/2008 - "We have evaluated effects of ATRA and As2O3 treatment in PML-RARalpha-negative HL60 promyelocytic leukemia cells, harboring amplified c-myc. "
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/01/2009 - "Within 14 acute myeloblastic leukemia patients, we confirmed 2 cases with FLT3-internal tandem duplication+, 1 patient with AML1-ETO, and only 1 case carrying a PML-RARalpha rearrangement. "
07/01/2008 - "Given that morphology of APL cases, as defined according to WHO criteria (95% of which carry the PML/RARalpha fusion gene), admits extremely divergent morphological pictures ofthe variant forms, we recommend these investigations to be performed in every case of de novo acute myeloid leukemia. "
02/01/2008 - "PML-RARalpha is the causative oncogene in 5% to 10% of the cases of acute myeloid leukemia. "
05/01/2006 - "In this issue of the Journal, Soucek et al. challenge the assumption that increased functional granulocytic maturation of HL-60, an ATRA-responsive acute myeloid leukemia cell line devoid of the APL-specific PML-RARalpha fusion protein, results in more rapid or more sustained cell death. "
09/01/2005 - "Given the specificities of these low benzodithiophene concentrations for PML-RARalpha and RARalpha, these drugs may be useful for combinatorial differentiation therapy of APL and possibly other acute myelogenous leukemia subtypes in which the overall ATRA signaling is suppressed."
11/01/2003 - "A total of 98 samples, comprising four groups, were evaluated: Group 1, 16 diagnostic samples molecularly positive by our existing laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 2, 51 diagnostic samples negative by our laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 3, 21 prospectively analyzed diagnostic cases, without prior molecular studies; and Group 4, 10 minimal residual disease (MRD) samples. "
06/01/2010 - "We suggest that alternative splicing of PML/RARalpha transcripts might be involved in NMD and each isoform should be quantified to further understand the pathogenesis of APL, stratify the risk of relapse, and monitor minimal residual disease."
01/01/2007 - "Longitudinal RT-PCR of PML/RARalpha allows sensitive assessment of response to treatment and minimal residual disease (MRD) monitoring in APL. "
03/01/2002 - "Acute promyelocytic leukaemia (APL) is characterized by the t(15;17)(q22;q21) leading to the formation of PML-RARalpha and RARalpha-PML fusion genes which provide suitable targets for the assessment of minimal residual disease (MRD). "
07/01/2001 - "Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method."
|5.||Hematologic Neoplasms (Hematological Malignancy)
|1.||Tretinoin (Retinoic Acid)
|2.||arsenic trioxide (Trisenox)
|3.||retinoic acid receptor alpha
|4.||Messenger RNA (mRNA)
|5.||Aligeron (AS 2)
|6.||Valproic Acid (Valproate, Semisodium)
|7.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|9.||Histone Deacetylase Inhibitors
|10.||RNA (Ribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Stem Cell Transplantation
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)